◀ Back to NUP43
MAP2K1 — NUP43
Text-mined interactions from Literome
Tseng et al., Biochem Biophys Res Commun 2001
:
To determine the involvement of MEK1-p42/p44 MAPK pathway in mediating DAB2 gene expression, we have performed the following experiments and found that ( i ) there was sustained activation of
p42/p44 MAPK, but not p38 MAPK, upon K562 cells differentiation ; ( ii ) application of MEK1 inhibitor U0126 reduced the expression of DAB2 protein, mRNA and promoter activity, as well as cell differentiation ; ( iii ) constitutively active
MEK1 increased DAB2 promoter activity ; and ( iv ) dominant negative ERK2 abolished constitutively active MEK1 induced DAB2 promoter activity
Utsugi et al., Eur J Pharmacol 2002
:
Furthermore,
mitogen activated protein kinase kinase ( MEK)-1-specific inhibitor, 2- ( 2-amino-3-methoxyphenyl ) -4H-1-benzopyran-4-one ( PD 98059 ),
blocked the lipopolysaccharide induced
p44/42 ERK activation and PDGF production
Lee et al., J Cell Physiol 2006
:
TNF-alpha enhanced expression of VCAM-1 protein and mRNA as well as phosphorylation of
p42/p44 MAPK, p38, and JNK were significantly
attenuated by inhibitors of
MEK1/2 ( U0126 ), p38 ( SB202190 ), and JNK ( SP600125 )
Gardner et al., J Biol Chem 1996
:
Pharmacological inhibition of
MEK-1 activity by incubation of cells with the compound PD 098059
blocked p42(MAPK) activation and FGF-2 protection against apoptosis